Atezolizumab and bevacizumab for HCC in the real world.
作者信息
Choo Su Pin, Nahon Pierre
机构信息
Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore.
AP-HP, Liver Unit, Hôpital Avicenne Bobigny, Université Sorbonne Paris Nord, Bobigny; Inserm, UMR-1138, Université de Paris, Paris, France.
出版信息
Liver Int. 2022 Apr;42(4):727-728. doi: 10.1111/liv.15204.
PMID:35289074
Abstract
摘要
相似文献
1
Atezolizumab and bevacizumab for HCC in the real world.阿替利珠单抗和贝伐单抗用于现实世界中的肝癌治疗。
Liver Int. 2022 Apr;42(4):727-728. doi: 10.1111/liv.15204.
2
Letter to the editor: Atezolizumab plus bevacizumab for hepatocellular carcinoma in the real world.致编辑的信：阿替利珠单抗联合贝伐单抗用于现实世界中的肝细胞癌治疗
Hepatology. 2022 Oct;76(4):E84-E85. doi: 10.1002/hep.32588. Epub 2022 Jun 6.
3
Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis.阿替利珠单抗联合贝伐单抗与索拉非尼作为不可切除肝细胞癌一线治疗的成本效益分析
Cancer Commun (Lond). 2020 Dec;40(12):743-745. doi: 10.1002/cac2.12110. Epub 2020 Nov 7.
4
Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗在不可切除肝细胞癌序贯治疗中的作用。
Anticancer Res. 2022 Mar;42(3):1403-1412. doi: 10.21873/anticanres.15610.
5
Response to the letter: "Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab".
Liver Int. 2024 Jul;44(7):1736-1737. doi: 10.1111/liv.15964. Epub 2024 May 8.
6
Clinical significance of the discrepancy between radiological findings and biochemical responses in atezolizumab plus bevacizumab for hepatocellular carcinoma.阿替利珠单抗联合贝伐单抗治疗肝细胞癌时影像学表现与生化反应差异的临床意义
Clin Mol Hepatol. 2022 Jul;28(3):575-579. doi: 10.3350/cmh.2022.0047. Epub 2022 Apr 21.
7
Outcomes of atezolizumab and bevacizumab for hepatocellular carcinoma: Does age matter?阿替利珠单抗和贝伐单抗治疗肝细胞癌的疗效：年龄有影响吗？
Liver Int. 2022 Dec;42(12):2597-2598. doi: 10.1111/liv.15434.
8
Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma.预测阿特珠单抗和贝伐珠单抗治疗肝细胞癌患者的结局。
Int J Mol Sci. 2023 Jul 22;24(14):11799. doi: 10.3390/ijms241411799.
9
Disease Control Achieved Using Atezolizumab + Bevacizumab in a Patient With Sarcomatoid Hepatocellular Carcinoma (SHCC), a Rare Variant Excluded From the IMbrave150 Trial.阿替利珠单抗联合贝伐珠单抗治疗肉瘤样肝细胞癌（SHCC）患者取得疗效，该患者为 IMbrave150 试验排除的罕见亚型。
J Investig Med High Impact Case Rep. 2022 Jan-Dec;10:23247096221129470. doi: 10.1177/23247096221129470.
10
Predictive factors for transition to conversion therapy in HCC using atezolizumab plus bevacizumab.使用阿替利珠单抗联合贝伐单抗治疗肝细胞癌时向转化治疗转变的预测因素。
Liver Int. 2024 Jul;44(7):1735. doi: 10.1111/liv.15944. Epub 2024 May 8.
引用本文的文献
1
Current perspectives on the pharmacological treatment of advanced hepatocellular carcinoma: a narrative review.晚期肝细胞癌药物治疗的当前观点：一项叙述性综述。
Ewha Med J. 2024 Oct;47(4):e53. doi: 10.12771/emj.2024.e53. Epub 2024 Oct 31.
2
Hepatocellular Carcinoma Immunotherapy: Predictors of Response, Issues, and Challenges.肝细胞癌免疫治疗：反应预测因素、问题与挑战。
Int J Mol Sci. 2024 Oct 15;25(20):11091. doi: 10.3390/ijms252011091.
Zotero 插件